Literature DB >> 20494037

Effects of aprotinin or tranexamic acid on proteolytic/cytokine profiles in infants after cardiac surgery.

Tain-Yen Hsia1, Tim C McQuinn, Rupak Mukherjee, Rachael L Deardorff, Jerry E Squires, Robert E Stroud, Fred A Crawford, Scott M Bradley, Scott T Reeves, Francis G Spinale.   

Abstract

BACKGROUND: After cardiopulmonary bypass (CPB), elaboration of cytokines, and subsequent induction of interstitial proteases, such as matrix metalloproteinases (MMPs), can result in a complex postoperative course. The serine protease inhibitor, aprotinin, which has been used in congenital heart surgery putatively for modulating fibrinolysis is now unavailable, necessitating the use of lysine analogues such as tranexamic acid (TXA). The present study tested the hypothesis that distinctly different plasma profiles of signaling molecules and proteases would be differentially affected after the administration of aprotinin or TXA in the context of congenital cardiac surgery and CPB.
METHODS: Thirty-seven patients (age, 4.8 +/- 0.3 months) undergoing corrective surgery for ventricular septal defect and tetralogy of Fallot received either aprotinin (n = 22) or TXA (n = 15). Using a high throughput multiplex suspension immunoassay, plasma was serially quantified for cytokines and MMPs: before aprotinin or TXA (baseline), after separation from CPB, and 4, 12, 24, and 48 hours post-CPB.
RESULTS: Tumor necrosis factor-alpha increased initially after CPB in both the aprotinin and TXA groups, but at 24 and 48 hours post-CPB was approximately 50% lower in the aprotinin group (p < 0.05). The IL-10 levels were threefold higher in the TXA group compared with the aprotinin group immediately post-CBP (p < 0.05). Plasma levels of MMP types associated with inflammation, MMP-8, and MMP-9, were twofold higher in the late post-CPB period in the TXA group when compared with the aprotinin group.
CONCLUSIONS: After ventricular septal defect or tetralogy of Fallot repair in children, cytokine induction occurs, which is temporally related to the emergence of a specific MMP profile. Moreover, these unique findings demonstrated differential effects between the serine protease inhibitor aprotinin and the lysine analogue TXA with respect to cytokine and MMP induction in the early postoperative period. The different cytokine-proteolytic profile between these antifibrinolytics may in turn influence biologic processes in the postoperative period. 2010 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20494037      PMCID: PMC3100188          DOI: 10.1016/j.athoracsur.2010.02.069

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  35 in total

1.  Aprotinin is safe in pediatric patients undergoing cardiac surgery.

Authors:  Carl L Backer; Angela M Kelle; Robert D Stewart; Sunitha C Suresh; Farah N Ali; Richard A Cohn; Roopa Seshadri; Constantine Mavroudis
Journal:  J Thorac Cardiovasc Surg       Date:  2007-10-22       Impact factor: 5.209

2.  A comparison of aprotinin and lysine analogues in high-risk cardiac surgery.

Authors:  Dean A Fergusson; Paul C Hébert; C David Mazer; Stephen Fremes; Charles MacAdams; John M Murkin; Kevin Teoh; Peter C Duke; Ramiro Arellano; Morris A Blajchman; Jean S Bussières; Dany Côté; Jacek Karski; Raymond Martineau; James A Robblee; Marc Rodger; George Wells; Jennifer Clinch; Roanda Pretorius
Journal:  N Engl J Med       Date:  2008-05-14       Impact factor: 91.245

3.  Aprotinin in primary cardiac surgery: operative outcome of propensity score-matched study.

Authors:  Dumbor L Ngaage; Alexander R Cale; Michael E Cowen; Steven Griffin; Levant Guvendik
Journal:  Ann Thorac Surg       Date:  2008-10       Impact factor: 4.330

4.  Collagenase-2 (MMP-8) and matrilysin-2 (MMP-26) expression in human wounds of different etiologies.

Authors:  Emma Pirilä; Jarkko T Korpi; Timo Korkiamäki; Tiina Jahkola; Ana Gutierrez-Fernandez; Carlos Lopez-Otin; Ulpu Saarialho-Kere; Tuula Salo; Timo Sorsa
Journal:  Wound Repair Regen       Date:  2007 Jan-Feb       Impact factor: 3.617

5.  Aprotinin during coronary-artery bypass grafting and risk of death.

Authors:  Sebastian Schneeweiss; John D Seeger; Joan Landon; Alexander M Walker
Journal:  N Engl J Med       Date:  2008-02-21       Impact factor: 91.245

6.  Differential effects of epsilon-aminocaproic acid and aprotinin on matrix metalloproteinase release in patients following cardiopulmonary bypass.

Authors:  Bruce H Dorman; Robert E Stroud; Michael M Wyckoff; James L Zellner; Don Botta; Amy H Leonardi; John S Ikonomidis; Francis G Spinale
Journal:  J Cardiovasc Pharmacol       Date:  2008-04       Impact factor: 3.105

7.  Increased inflammation delays wound healing in mice deficient in collagenase-2 (MMP-8).

Authors:  Ana Gutiérrez-Fernández; Masaki Inada; Milagros Balbín; Antonio Fueyo; Ana S Pitiot; Aurora Astudillo; Kenji Hirose; Michiko Hirata; Steven D Shapiro; Agnès Noël; Zena Werb; Stephen M Krane; Carlos López-Otín; Xose S Puente
Journal:  FASEB J       Date:  2007-03-28       Impact factor: 5.191

8.  Impact of aprotinin on adverse clinical outcomes and mortality up to 12 years in a registry of 3,337 patients.

Authors:  Stephen A Olenchock; Peter H U Lee; Tamar Yehoshua; Sabina A Murphy; James Symes; George Tolis
Journal:  Ann Thorac Surg       Date:  2008-08       Impact factor: 4.330

9.  Randomized trial of hematocrit 25% versus 35% during hypothermic cardiopulmonary bypass in infant heart surgery.

Authors:  Jane W Newburger; Richard A Jonas; Janet Soul; Barry D Kussman; David C Bellinger; Peter C Laussen; Richard Robertson; John E Mayer; Pedro J del Nido; Emile A Bacha; Joseph M Forbess; Frank Pigula; Stephen J Roth; Karen J Visconti; Adre J du Plessis; David M Farrell; Ellen McGrath; Leonard A Rappaport; David Wypij
Journal:  J Thorac Cardiovasc Surg       Date:  2008-02       Impact factor: 5.209

10.  Aprotinin and renal dysfunction after pediatric cardiac surgery.

Authors:  Andrea Székely; Erzsébet Sápi; Tamás Breuer; Miklós D Kertai; Gábor Bodor; Péter Vargha; András Szatmári
Journal:  Paediatr Anaesth       Date:  2008-02       Impact factor: 2.556

View more
  5 in total

1.  Differential effects of aprotinin and tranexamic acid on outcomes and cytokine profiles in neonates undergoing cardiac surgery.

Authors:  Eric M Graham; Andrew M Atz; Jenna Gillis; Stacia M Desantis; A Lauren Haney; Rachael L Deardorff; Walter E Uber; Scott T Reeves; Francis X McGowan; Scott M Bradley; Francis G Spinale
Journal:  J Thorac Cardiovasc Surg       Date:  2011-11-09       Impact factor: 5.209

2.  The safety and efficacy of antifibrinolytic therapy in neonatal cardiac surgery.

Authors:  Chih-Yuan Lin; Jeffery H Shuhaiber; Hugo Loyola; Hua Liu; Pedro Del Nido; James A DiNardo; Frank A Pigula
Journal:  PLoS One       Date:  2015-05-08       Impact factor: 3.240

3.  Tranexamic acid reduces hidden blood loss in the treatment of intertrochanteric fractures with PFNA: a single-center randomized controlled trial.

Authors:  Jinlai Lei; Binfei Zhang; Yuxuan Cong; Yan Zhuang; Xing Wei; Yahui Fu; Wei Wei; Pengfei Wang; Shiming Wen; Hai Huang; Hu Wang; Shuang Han; Shuguang Liu; Kun Zhang
Journal:  J Orthop Surg Res       Date:  2017-08-15       Impact factor: 2.359

Review 4.  Inflammation and Oxidative Stress in the Context of Extracorporeal Cardiac and Pulmonary Support.

Authors:  Sanaz Hatami; Joshua Hefler; Darren H Freed
Journal:  Front Immunol       Date:  2022-03-04       Impact factor: 7.561

Review 5.  Inhibition of metalloproteinases in therapy for severe lung injury due to COVID-19.

Authors:  B Solun; Y Shoenfeld
Journal:  Med Drug Discov       Date:  2020-06-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.